rs483352897
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000263.4(NAGLU):βc.507_516delβ(p.Ser169ArgfsTer13) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000223 in 1,614,052 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.000026 ( 0 hom., cov: 35)
Exomes π: 0.000022 ( 0 hom. )
Consequence
NAGLU
NM_000263.4 frameshift
NM_000263.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 9.47
Genes affected
NAGLU (HGNC:7632): (N-acetyl-alpha-glucosaminidase) This gene encodes an enzyme that degrades heparan sulfate by hydrolysis of terminal N-acetyl-D-glucosamine residues in N-acetyl-alpha-D-glucosaminides. Defects in this gene are the cause of mucopolysaccharidosis type IIIB (MPS-IIIB), also known as Sanfilippo syndrome B. This disease is characterized by the lysosomal accumulation and urinary excretion of heparan sulfate. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 17-42537516-TGGAGCGGCCA-T is Pathogenic according to our data. Variant chr17-42537516-TGGAGCGGCCA-T is described in ClinVar as [Pathogenic]. Clinvar id is 1564.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NAGLU | NM_000263.4 | c.507_516del | p.Ser169ArgfsTer13 | frameshift_variant | 2/6 | ENST00000225927.7 | NP_000254.2 | |
NAGLU | XM_024450771.2 | c.564_573del | p.Ser188ArgfsTer13 | frameshift_variant | 3/7 | XP_024306539.1 | ||
NAGLU | XM_047436138.1 | c.-78-818_-78-809del | intron_variant | XP_047292094.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NAGLU | ENST00000225927.7 | c.507_516del | p.Ser169ArgfsTer13 | frameshift_variant | 2/6 | 1 | NM_000263.4 | ENSP00000225927 | P1 | |
NAGLU | ENST00000590358.1 | c.195_204del | p.Ser65ArgfsTer13 | frameshift_variant | 1/2 | 4 | ENSP00000466892 | |||
NAGLU | ENST00000586516.5 | c.134-818_134-809del | intron_variant | 2 | ENSP00000467135 | |||||
NAGLU | ENST00000591587.1 | c.127-818_127-809del | intron_variant | 5 | ENSP00000467836 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152250Hom.: 0 Cov.: 35
GnomAD3 genomes
AF:
AC:
4
AN:
152250
Hom.:
Cov.:
35
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251134Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135850
GnomAD3 exomes
AF:
AC:
3
AN:
251134
Hom.:
AF XY:
AC XY:
2
AN XY:
135850
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000219 AC: 32AN: 1461802Hom.: 0 AF XY: 0.0000179 AC XY: 13AN XY: 727208
GnomAD4 exome
AF:
AC:
32
AN:
1461802
Hom.:
AF XY:
AC XY:
13
AN XY:
727208
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152250Hom.: 0 Cov.: 35 AF XY: 0.0000269 AC XY: 2AN XY: 74378
GnomAD4 genome
AF:
AC:
4
AN:
152250
Hom.:
Cov.:
35
AF XY:
AC XY:
2
AN XY:
74378
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Mucopolysaccharidosis, MPS-III-B Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 23, 2021 | Variant summary: NAGLU c.507_516del10 (p.Ser169ArgfsX13) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 1.2e-05 in 251134 control chromosomes (gnomAD). c.507_516del10 (also known as 503del10 in the literature) has been reported in the literature in multiple individuals (both homozygous and compound heterozygous) affected with Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome B) (example: Beesley_2004, Weber_1999, Zhao_1998) . These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 11, 1996 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Dec 15, 2020 | - - |
Mucopolysaccharidosis, MPS-III-B;C5569050:Charcot-Marie-Tooth disease axonal type 2V Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 17, 2024 | This sequence change creates a premature translational stop signal (p.Ser169Argfs*13) in the NAGLU gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NAGLU are known to be pathogenic (PMID: 9832037, 10094189, 16151907). This variant is present in population databases (rs483352897, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with Sanfilippo syndrome type B (PMID: 8650226). ClinVar contains an entry for this variant (Variation ID: 1564). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 05, 2022 | - - |
Hepatosplenomegaly;C0020555:Hypertrichosis;C0036857:Intellectual disability, severe;C0424503:Abnormal facial shape;C1845847:Coarse facial features;C1853487:Thick eyebrow;C4021768:Abnormality of metabolism/homeostasis;C4024726:Mucopolysacchariduria Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2017 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 25, 2022 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 14984474, 8650226, 16151907, 9443875, 9832037, 26147798, 10094189) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at